Targeted Drug with Chemotherapy Combo Offers Longer Life to Patients with B-cell Cancers

Mayo Clinic: Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial. Led by Mayo Clinic, researchers found that ibrutinib and chemotherapy (bendamustine and rituximab, known as BR) reduced the risk of death or cancer progression by almost 80 percent in patients with previously treated CLL or SLL, compared to use of BR alone.

Young Adult Survivors Most Distressed After Leukemia and Lymphoma Treatment

Colorado University. US: Two University of Colorado Cancer Center studies published in the Journal of Psychosocial Oncology show that young adult survivors (ages 18-39) of leukemia and lymphoma are more likely to report high distress than older survivors (ages 65+).

Computer model of blood development could speed up search for new leukaemia drugs

Cambridge University. UK: The first comprehensive computer model to simulate the development of blood cells could help in the development of new treatments for leukaemia and lymphoma, say researchers at the University of Cambridge and Microsoft Research.

Mechanism of Disease Progression in Conjunctival Lymphoma is Clarified- Contributing to the Development of a Curative Drug-

Hokudai University. Japan: Conjunctiva is the tissue that covers the surface of the eye, and is the first line of defense against pathogens from the outside. This defense mechanism is an immune mechanism controlled by the conjunctival lymphoid, which activates lymphocyte type B-cells, T-cells, and dendritic cells, when a pathogen is detected. The most frequent tissue type of malignant lymphoma on conjunctiva is extranodal marginal zone B-cell lymphoma, which is observed in 7% of cases of non-Hodgkin’s B-cell lymphoma⁴⁾.

Non-Hodgkin's Lymphoma

author: Dr. Lawrence D. Kaplan University of california San Francisco 2008-07-28
Introduction

Non-Hodgkin’s lymphoma (NHL) is a cancer of lymphocytes, a type of white blood cell that plays an important role in the immune system. At present, more than 20 different types of non-Hodgkin’s lymphoma have been identified. The choice of how to treat a lymphoma may be dependent on being able to identify the precise NHL subtype. Survival rate also tends to be dependent upon the type of lymphoma.

Hodgkin Lymphoma

Author: Dr Joseph Connors British Columbia Cancer Agency 2008-07-28

Introduction

Hodgkin lymphoma is a cancer that originates from B-lymphocytes of the immune system and the most common type is marked by the presence of a very specific type of cell known as the Hodgkin Reed-Sternberg cell. Once a uniformly fatal disease, today Hodgkin lymphoma is routinely curable. This knol provides a history of the disease and then goes on to describe the typical symptoms, diagnosis, treatment options, and prognosis after treatment.